News just out:
IMMP is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B. The decision follows a preliminary safety and efficacy review by the Data Monitoring Committee and its recommendation, based on the patients recruited in Stage 1 of Part B
News just out: IMMP is pleased to report it has decided to...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 42705 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |